Management

Pierre Vandepapeliere

CEO & CMO

Pierre Vandepapelière, CEO & CMO

Senior executive leader with over 25 years global experience in development of prophylactic and therapeutic vaccines. Pierre has extended worldwide experience in a large vaccine company and in small Biotech companies, with leading roles in clinical development, regulatory & medical affairs, commercial, legal, business development.

Medical Doctor, PhD, Trop Med Dip, Pierre has expertise in vaccines, infectious diseases, immunology, auto immune and inflammatory diseases, adjuvants, with numerous publications and patents. Before joining Imcyse, Pierre was Vice-President, Chief Medical Officer, at Neovacs and Abivax, Paris, France. He was also Consultant for other Biotech companies. Before and during 18 years, Pierre has occupied various management positions in development of vaccines in GlaxoSmithKline Vaccines, Rixensart, Belgium. Pierre joined Imcyse in March 2015.

Jean Smal

PhD, VP Head of Development

Jean Smal, PhD, VP Head of Development

Senior executive leader with global experience in the R&D and Manufacturing Vaccine Industry. Jean is a bioengineer and owns a PhD in biochemistry. As Head of the technical development at GlaxoSmithKline Vaccines, he has developed a huge experience of the development of new vaccines with an end to end view, from the design of the antigens to the final commercial production scale. During the last 10 years he directly contributed to the development and the launch of 12 new vaccines. Before, Jean occupied various positions from project leader to general manager at Eurogentec/ Pharos, Seraing, Belgium, a Biotech Company offering services in biopharmaceutical product development and production of GMP lots for clinical trials. Jean joined Imcyse in September 2015.

Marcelle Van Mechelen

PhD, Senior Scientific Adviser

Marcelle Van Mechelen, PhD, Senior Scientific Adviser 

Marcelle has a 28 years experience in immunology, biotechnology and vaccinology. She owns PhD and Post Doc in immmunology on innate and adaptive immunity ULB (1987- 1995). Between 1995 and 2015, she worked in research and immunology at GSK vaccines as Vice President Vaccine Research / Research and Preclinical development GSK from 2012 onwards. Marcelle joined in March 2016.

Vincent Carlier

PhD, Head of Product Development

Vincent Carlier, PhD, Head of Product Development

Background : Vincent has worked for over 20 years with Prof. JM St Remy on Imcyse technology

Marie Gérard

Corporate Services Manager

Marie Gérard, Corporate Services Manager : HR, accounting, corp communication, IT

Background : 2006-2015: QA, QC & HR Manager, KitoZyme S.A, Liège

Marie joined in September 2015.

Yves Lobet

PhD, Head Project Management

Yves Lobet, PhD, Head Project Management

Background : 1989-2013: GSK Vaccines: Mol Biol, pre clinical RD, RD Partnerships, Project mgt, Competitive Intelligence.

Yves joined in September 2015.

Luc Vander Elst

PhD, Head of Preclinical Development

 Luc Vander Elst, PhD, Head of Preclinical Development

Background : Luc has worked for over 20 years with Prof. JM St Remy on Imcyse technology

Geoffrey Gloire

PhD, IP Manager

Geoffrey Gloire, PhD, IP Manager

After a PhD in molecular biology at the University of Liège, and a post doc in Paris, Geoffrey was Patent Advisor in Life Sciences at ULg’s Technology Transfer Office from 2011 until June 2016 when he joined Imcyse

Jean Van Rampelbergh

PhD, Clinical project Management

Jean Van Rampelbergh, PhD, Clinical Project Management

Former clinical director Sanofi Belgium, Jean joined in March 2016

 

With the support of external experts:

  • Finances: Thibault Cloostermans, DC Corporate Finance
  • Regulatory and Quality Assurance: RLM Consulting
    René Mignolet, PhD, MBA & Charline Lays, Bio-engineer, MBA, Regulatory Affairs Manager QA/Compliance Manager.
  • Toxicology: Rommel Consulting
    Eddy Rommel, PhD & Frédéric Schynts, PhD